Hyundai Motor America launched its 16th year in the battle against pediatric cancer and has awarded $86 million in research funding. An article on the website examiner.com reports that Hyundai has, this year, awarded funds for a clinical trail for rhabdomyosarcoma.
“Dr. Leo Mascarenhas [a member of the FocusOnRhabdo Scientific Advisory Council] of Children’s Hospital Los Angeles was awarded funds for a pilot clinical trial investigating the combination of vinorelbine, actinomycin-D and cyclophosphamide for the treatment of adolescents and young adults with rhabdomyosarcoma, a deadly cancer of muscular tissue. Teens and young adults have a much poorer prognosis when compared to children with cancer. Many reasons contribute to this sad statistic. They include higher incidence of unfavorable histology, more advanced disease when first diagnosed, lack of uniformity in treatment protocols, and a variety of socioeconomic stressors experienced by this age group. The clinical trial will evaluate the feasibility and toxicity of this treatment and response rate in rhabdomyosarcoma; it will also investigate the pharmacokinetics of vinorelbine when administered with actinomycin-D and cyclophosphamide. (Pharmacokinetics is a branch of pharmacology focused on determining the fate of substances administered externally to a living organism.) In addition, because data for rhabdomyosarcoma in this age group is lacking, tumor genomes will be profiled and it will be compared to existing data available in children. This may result in a better understanding of the biology of rhabdomyosarcoma in this age group and identify molecular targets for agents that could be combined with cytotoxic chemotherapy to improve outcomes.”
You can read the full article here.